Han Zeng

发表

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, Journal for ImmunoTherapy of Cancer.

Clinical value and feasibility of ISET in detecting circulating tumor cells in early breast cancer

G. Ma, Xiaoan Liu, Jingyi Wang, 2020, Translational cancer research.

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

Le Xu, Yuan Chang, Baoying Hu, 2021, Cancer Immunology, Immunotherapy.

Poor clinical outcomes and immunoevasive contexture in interleukin‐9 abundant muscle‐invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, International journal of cancer.

Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

Y. Zhu, Le Xu, Weijuan Zhang, 2022, British Journal of Cancer.

Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Hongyi Zhang, 2022, Cancer Immunology, Immunotherapy.

B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.

Le Xu, Jiejie Xu, Yu Zhu, 2022, European journal of cancer.

Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Le Xu, Yuan Chang, Jiejie Xu, 2021, Journal for ImmunoTherapy of Cancer.

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

Le Xu, Jiejie Xu, Shengming Jin, 2022, Annals of Surgical Oncology.

Tumor-infiltrating TNFRSF9+ CD8+ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response

Le Xu, Yuan Chang, Jiejie Xu, 2020, Oncoimmunology.

Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis

Le Xu, Yuan Chang, Jiejie Xu, 2021, Cancer Immunology, Immunotherapy.

Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer

B. Dai, Le Xu, Yuan Chang, 2020, Cancer Research.

Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients

B. Dai, Le Xu, Yuan Chang, 2020, Cancer Immunology, Immunotherapy.

PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients.

B. Dai, Le Xu, Yuan Chang, 2019, Urologic oncology.

Tumor-infiltrating IL-17A+ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, British Journal of Cancer.

Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.

B. Dai, Le Xu, Yuan Chang, 2019, European urology.

Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, Journal for ImmunoTherapy of Cancer.

Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.

Le Xu, Yuan Chang, Baoying Hu, 2022, Urologic oncology.

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for immunotherapy of cancer.

Intratumoral IL22‐producing cells define immunoevasive subtype muscle‐invasive bladder cancer with poor prognosis and superior nivolumab responses

B. Dai, Le Xu, Yuan Chang, 2020, International journal of cancer.

Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Li Liu, 2022, British Journal of Cancer.

Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.

Y. Zhu, Le Xu, Jiejie Xu, 2023, Urologic oncology.

Effect of inactivated COVID-19 vaccination on pregnancy outcomes following frozen-thawed embryo transfer: A retrospective cohort study

Jiaying Lin, Jialyu Huang, You Li, 2022, International Immunopharmacology.

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, Cancer Immunology, Immunotherapy.

Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5+ CD8+ T cell abundance

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Yu Zhu, 2024, British journal of cancer.

Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Weijuan Zhang, Zewei Wang, 2023, BMC Cancer.